Pharmaceuticals
BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds f...
2025-09-02 20:30
6495
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
* Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 * Rising demand for 2-dose regimen as international standards amid projected global market growth toUSD 6.3 billion by 3034 * SKBS continues strategic R&D to enhance global vaccine comp...
2025-09-02 19:00
4123
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine...
2025-09-02 17:52
3094
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination the...
2025-09-02 16:00
2186
LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company
Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEOJames Park) today announced that it has entered a late-stage to commercial contract manufacturing par...
2025-09-02 08:00
5787
Norma Completes Quantum AI Algorithm Validation on NVIDIA
"Quantum AI up to 73x Faster on NVIDIA CUDA-Q" * Norma, a quantum computing company, has validated the performance of quantum AI algorithms using NVIDIA CUDA-Q. * By running these algorithms for drug development on CUDA-Q, Norma observed computational speeds up to 73 times faster. * The com...
2025-09-01 21:00
2753
AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction
* AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success * 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics * 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the ...
2025-09-01 21:00
2234
Jenscare, releases 2025H1 interim results
BEIJING, Sept. 1, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs, achieved milestones in its product portfolio globally, and just released its interim results for 2025H1 endedJune 30, 2025...
2025-09-01 13:00
6004
Jacobio Pharma Announces 2025 Interim Results
BEIJING and SHANGHAI and BOSTON, Aug. 29, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months endedJune 30, 2025. During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same per...
2025-08-30 00:25
6809
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
* Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion * Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market onAugust 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YO...
2025-08-29 19:30
3442
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
* 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies * Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in chil...
2025-08-29 14:00
3082
Everest Medicines Announces Interim Results for First Half of 2025
SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 a...
2025-08-29 07:52
4861
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hema...
2025-08-28 22:00
1873
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
* Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treate...
2025-08-28 21:00
5049
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-28 20:00
4759
ACROBiosystems and DAAN Biotherapeutics Sign Strategic MOU for the Development of Precision Immuno-Oncology Therapeutics
SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ -- ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutic...
2025-08-28 09:54
4287
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...
2025-08-28 07:45
4162
Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study
- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. - Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron...
2025-08-28 07:45
2089
Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand
HONG KONG, Aug. 27, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across...
2025-08-27 23:09
3250
Harbour BioMed Reports 2025 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its i...
2025-08-27 22:40
3570
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1169 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1130 media titles]
2026-11-05 06:52Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-06 22:06
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
[Picked up by 1073 media titles]
2026-11-05 22:05
Most Read
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
62481
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
27852
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
21630
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
18942